Proposal for a New Classification of Rare Cancers Adopting Updated Histological Tumor Types.

IF 2.5 4区 医学 Q2 PATHOLOGY
Ryoko Rikitake, Yasushi Yatabe, Yoko Yamamoto, Tatsunori Shimoi, Shintaro Iwata, Yasushi Goto, Yu Mizushima, Akira Kawai, Takahiro Higashi
{"title":"Proposal for a New Classification of Rare Cancers Adopting Updated Histological Tumor Types.","authors":"Ryoko Rikitake, Yasushi Yatabe, Yoko Yamamoto, Tatsunori Shimoi, Shintaro Iwata, Yasushi Goto, Yu Mizushima, Akira Kawai, Takahiro Higashi","doi":"10.1111/pin.70021","DOIUrl":null,"url":null,"abstract":"<p><p>Several classifications have been proposed to define rare cancers; however, the pathophysiological understanding of tumors evolves rapidly. We propose a New Classification of Rare Cancer (NCRC) using the updated International Classification of Diseases for Oncology 3.2 coding system and World Health Organization Classification of Tumors 5th edition. We applied patient data recorded in the National Cancer Registry of Japan to the new classification, setting a cut-off of a crude incidence rate of 6 cases/100 000/year to define rare cancers, and developed a list of rare cancers in Japan from 2016 to 2019. The NCRC system identified various rare cancers, comprising 20.0% of all cancer diagnoses in this period. To examine this classification system's performance, we compared rare/non-rare labeling of cancers by the Surveillance of Rare Cancers in Europe (RARECARENet) project and NCRC system. Compared with cases using the RARECARENet classification in Europe, 69 351 cases/year (6.8%) switched status with our classification, with 45 293 and 232 109 cases (4 years) switching from rare and non-rare, respectively. Major differences included diffuse large B-cell lymphomas, some thyroid cancers, oral cavity and lip cancers, and squamous cell carcinoma of the uterine cervix. As the NCRC includes newly classified tumor entities, it warrants validation using other diverse cohorts.</p>","PeriodicalId":19806,"journal":{"name":"Pathology International","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pin.70021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Several classifications have been proposed to define rare cancers; however, the pathophysiological understanding of tumors evolves rapidly. We propose a New Classification of Rare Cancer (NCRC) using the updated International Classification of Diseases for Oncology 3.2 coding system and World Health Organization Classification of Tumors 5th edition. We applied patient data recorded in the National Cancer Registry of Japan to the new classification, setting a cut-off of a crude incidence rate of 6 cases/100 000/year to define rare cancers, and developed a list of rare cancers in Japan from 2016 to 2019. The NCRC system identified various rare cancers, comprising 20.0% of all cancer diagnoses in this period. To examine this classification system's performance, we compared rare/non-rare labeling of cancers by the Surveillance of Rare Cancers in Europe (RARECARENet) project and NCRC system. Compared with cases using the RARECARENet classification in Europe, 69 351 cases/year (6.8%) switched status with our classification, with 45 293 and 232 109 cases (4 years) switching from rare and non-rare, respectively. Major differences included diffuse large B-cell lymphomas, some thyroid cancers, oral cavity and lip cancers, and squamous cell carcinoma of the uterine cervix. As the NCRC includes newly classified tumor entities, it warrants validation using other diverse cohorts.

采用最新组织学肿瘤类型的罕见癌症新分类的建议。
人们提出了几种分类来定义罕见的癌症;然而,对肿瘤的病理生理认识发展迅速。我们提出了一个新的罕见癌症分类(NCRC),使用更新的国际肿瘤疾病分类3.2编码系统和世界卫生组织肿瘤分类第5版。我们将日本国家癌症登记处记录的患者数据应用到新的分类中,以6例/10万/年的粗发病率为临界值来定义罕见癌症,并制定了2016年至2019年日本罕见癌症列表。NCRC系统确定了各种罕见的癌症,占同期所有癌症诊断的20.0%。为了检验该分类系统的性能,我们比较了欧洲罕见癌症监测(RARECARENet)项目和NCRC系统对罕见/非罕见癌症的标记。与欧洲使用RARECARENet分类的病例相比,69 351例/年(6.8%)切换到我们的分类,45 293例和232 109例(4年)分别从罕见和非罕见转换。主要的区别包括弥漫性大b细胞淋巴瘤、某些甲状腺癌、口腔癌和唇癌以及子宫颈鳞状细胞癌。由于NCRC包括新分类的肿瘤实体,因此需要使用其他不同的队列进行验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathology International
Pathology International 医学-病理学
CiteScore
4.50
自引率
4.50%
发文量
102
审稿时长
12 months
期刊介绍: Pathology International is the official English journal of the Japanese Society of Pathology, publishing articles of excellence in human and experimental pathology. The Journal focuses on the morphological study of the disease process and/or mechanisms. For human pathology, morphological investigation receives priority but manuscripts describing the result of any ancillary methods (cellular, chemical, immunological and molecular biological) that complement the morphology are accepted. Manuscript on experimental pathology that approach pathologenesis or mechanisms of disease processes are expected to report on the data obtained from models using cellular, biochemical, molecular biological, animal, immunological or other methods in conjunction with morphology. Manuscripts that report data on laboratory medicine (clinical pathology) without significant morphological contribution are not accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信